Search

Displaying results 9401 - 9410 of 10000 in total
  1. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    Contulakin-G is a broad spectrum non-opioid analgesic. It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  2. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  3. Drug

    Tonabersat

    go.drugbank.com/drugs/DB06578
    Investigational

  4. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

    Synonyms: 1-Chloro-N- (hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide, 1-Chloro-N-(hydroxyformylmethyl-4-hydroxyisoquinoline-3-carboxamide
  5. Drug

    Valomaciclovir

    go.drugbank.com/drugs/DB06575
    Investigational

  6. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  7. Drug

    Adenosine 5'-phosphosulfate

    go.drugbank.com/drugs/DB03708
    Investigational

    The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.

  8. Drug

    Emibetuzumab

    go.drugbank.com/drugs/DB11849
    Investigational

    Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.

  9. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  10. Drug

    Skin-derived ABCB5-positive Mesenchymal Stem cells

    go.drugbank.com/drugs/DB17862
    Investigational

    Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).

    Synonyms: allo-APZ2-EB